Pulmonary delivery of active fragments of parathyroid hormone

Details Pulmonary delivery of active fragments of parathyroid hormone Pulmonary delivery of active fragments of parathyroid hormone

2000-05-22

2008-11-25

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000, C530S399000, C424S045000, C424S469000

Reexamination Certificate

active

07456150

ABSTRACT:
Systemic delivery of parathyroid hormone to a mammalian host is accomplished by inhalation through the mouth of a dispersion of an N-terminal fragment of PTH. It has been found that such respiratory delivery of the PTH fragment provides a pulsatile concentration profile of the PTH in the host's serum. PTH fragment compositions include dry powder formulations having the PTH present in a dry bulking powder, liquid solutions or suspensions suitable for nebulization, and aerosol propellants suitable for use in a metered dose inhaler.

REFERENCES:
patent: 4698328 (1987-10-01), Neer et al.
patent: 4833125 (1989-05-01), Neer et al.
patent: 5011678 (1991-04-01), Wang et al.
patent: 5230884 (1993-07-01), Evans et al.
patent: 5302581 (1994-04-01), Sarin et al.
patent: 5458135 (1995-10-01), Patton et al.
patent: 5563122 (1996-10-01), Endo et al.
patent: 5578567 (1996-11-01), Cardinaux et al.
patent: 2248550 (1992-04-01), None
Neer et al. (1987) Osteoporosis 53:829-835.
Hesch et al. (1988) Calcif. Tisue Int. 42:341-344.
Habener et al. (1971) Proc. Natl. Acad. Sci. USA 68:2986-2991.
Patton et al. (1992) Adv. Drug Delivery Reviews 8:179-196.
Harms et al. (1987) Int. Symp. On Osteoporisis, Aalborg, Abstr. 232:723-724.
Patton (1994) J. Controlled Release 28: 79-85.
Abstract of Japanese Patent, Document No. JP 02 000111, Date Jan. 5, 1990.
Patton, “Deep-lung delivery of proteins”, Modern Drug Discovery, Sep./Oct. 1998; pp. 19-28.
Hodsman et al., “Biochemical Responses to Sequential Human Parathyroid Hormone (1-38) and Calcitonin in Osteoporotic Patients,” Bone and Mineral (1990), vol. 9, p. 137-152.
Hodsman et al., “Bone Densitometric and Histomorphometric Responses to Seqential Human Parathyroid Hormone (1-38) and Salmon Calcitonin in Osteoporotic Patients,” Bone and Mineral (1991), vol. 14, p. 67-83.
Beaucage et al., “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis,” Tetrahedron Letters (1981), vol. 22(2), p. 1859-1862.
Hesch et al., “First Clinical Observations with hPTH(1-38), a More Potent Human Parathyroid Hormone Peptide,” Horm. Metabol. Res. (1984), vol. 16, p. 559-560.

Affiliated with

Also associated with

Rating

Pulmonary delivery of active fragments of parathyroid hormone does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pulmonary delivery of active fragments of parathyroid hormone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pulmonary delivery of active fragments of parathyroid hormone will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4030527